Woman's case prompts contraceptive scrutiny

Switzerland's medicines supervisor says it will analyse all birth control pills after a young woman suffered a lung embolism possibly linked to a contraceptive.

This content was published on June 12, 2009 - 10:43

A spokesman for the Swiss Agency for Therapeutics (Swissmedic) told Swiss television late on Thursday that it had collected extensive research on various birth control pills and would come to a finding on their health effects in the autumn.

The announcement comes after a 16-year-old woman suffered a lung embolism that left her severely disabled. She had been taking Yasmin birth-control pills produced by Germany's Bayer company.

Bayer contends the drug presents no more risk for venal thrombosis than other contraceptive pills.

"We assume that Swissmedic's analysis concerning Yasmin will yield no new findings because Yasmin is one of the most well researched birth-control pills worldwide," the company said. with agencies

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.